DE60317045T2 - Verfahren und nukleinsäuren zur analyse von störungen der proliferation kolorektaler zellen - Google Patents
Verfahren und nukleinsäuren zur analyse von störungen der proliferation kolorektaler zellen Download PDFInfo
- Publication number
- DE60317045T2 DE60317045T2 DE60317045T DE60317045T DE60317045T2 DE 60317045 T2 DE60317045 T2 DE 60317045T2 DE 60317045 T DE60317045 T DE 60317045T DE 60317045 T DE60317045 T DE 60317045T DE 60317045 T2 DE60317045 T2 DE 60317045T2
- Authority
- DE
- Germany
- Prior art keywords
- seq
- dna
- methylation
- sequence
- eya4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 103
- 150000007523 nucleic acids Chemical class 0.000 title claims description 69
- 108020004707 nucleic acids Proteins 0.000 title claims description 64
- 102000039446 nucleic acids Human genes 0.000 title claims description 64
- 230000035755 proliferation Effects 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 74
- 210000001072 colon Anatomy 0.000 claims abstract description 35
- 230000002062 proliferating effect Effects 0.000 claims abstract description 35
- 238000003745 diagnosis Methods 0.000 claims abstract description 9
- 108020004414 DNA Proteins 0.000 claims description 94
- 238000007069 methylation reaction Methods 0.000 claims description 87
- 230000011987 methylation Effects 0.000 claims description 86
- 239000000523 sample Substances 0.000 claims description 82
- 238000003556 assay Methods 0.000 claims description 57
- 238000004458 analytical method Methods 0.000 claims description 44
- 101000938422 Homo sapiens Eyes absent homolog 4 Proteins 0.000 claims description 37
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 34
- 102100030910 Eyes absent homolog 4 Human genes 0.000 claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
- 238000009396 hybridization Methods 0.000 claims description 33
- 201000010099 disease Diseases 0.000 claims description 32
- 230000000295 complement effect Effects 0.000 claims description 30
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 29
- 239000002773 nucleotide Substances 0.000 claims description 26
- 125000003729 nucleotide group Chemical group 0.000 claims description 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 26
- 210000001519 tissue Anatomy 0.000 claims description 25
- 238000001514 detection method Methods 0.000 claims description 24
- 239000012634 fragment Substances 0.000 claims description 24
- 108091029430 CpG site Proteins 0.000 claims description 23
- 230000003321 amplification Effects 0.000 claims description 23
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 23
- 239000003153 chemical reaction reagent Substances 0.000 claims description 21
- 101150098472 eya4 gene Proteins 0.000 claims description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 17
- 229940104302 cytosine Drugs 0.000 claims description 16
- 238000012360 testing method Methods 0.000 claims description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 230000001105 regulatory effect Effects 0.000 claims description 12
- 238000012163 sequencing technique Methods 0.000 claims description 11
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 10
- 230000014509 gene expression Effects 0.000 claims description 10
- 108020004999 messenger RNA Proteins 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 10
- 230000007423 decrease Effects 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 241000270295 Serpentes Species 0.000 claims description 6
- 208000009956 adenocarcinoma Diseases 0.000 claims description 6
- 239000012472 biological sample Substances 0.000 claims description 6
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 claims description 6
- 238000003018 immunoassay Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 238000001574 biopsy Methods 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000001124 body fluid Anatomy 0.000 claims description 5
- 239000010839 body fluid Substances 0.000 claims description 5
- 229940035893 uracil Drugs 0.000 claims description 5
- 208000019399 Colonic disease Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079826 hydrogen sulfite Drugs 0.000 claims description 4
- 108091008146 restriction endonucleases Proteins 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 230000009466 transformation Effects 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000002458 carcinoid tumor Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000017572 squamous cell neoplasm Diseases 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract description 52
- 108090000623 proteins and genes Proteins 0.000 abstract description 44
- 230000002068 genetic effect Effects 0.000 abstract description 11
- 230000001973 epigenetic effect Effects 0.000 abstract description 9
- 230000004069 differentiation Effects 0.000 abstract description 8
- 230000030933 DNA methylation on cytosine Effects 0.000 abstract description 6
- 238000012544 monitoring process Methods 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 21
- 238000003752 polymerase chain reaction Methods 0.000 description 20
- 208000029742 colonic neoplasm Diseases 0.000 description 18
- 206010009944 Colon cancer Diseases 0.000 description 17
- 108091029523 CpG island Proteins 0.000 description 15
- 239000011159 matrix material Substances 0.000 description 15
- 230000035945 sensitivity Effects 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 14
- 239000000872 buffer Substances 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000002405 diagnostic procedure Methods 0.000 description 9
- 208000003200 Adenoma Diseases 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000007790 solid phase Substances 0.000 description 8
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 7
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 108091093088 Amplicon Proteins 0.000 description 6
- 230000007067 DNA methylation Effects 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 208000032818 Microsatellite Instability Diseases 0.000 description 6
- 239000012491 analyte Substances 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 231100000357 carcinogen Toxicity 0.000 description 4
- 239000003183 carcinogenic agent Substances 0.000 description 4
- 238000003795 desorption Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 230000006607 hypermethylation Effects 0.000 description 4
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 102000054765 polymorphisms of proteins Human genes 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 238000004611 spectroscopical analysis Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 208000009575 Angelman syndrome Diseases 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- -1 Phosphorothioate nucleic acids Chemical class 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 201000006069 autosomal dominant nonsyndromic deafness 10 Diseases 0.000 description 2
- 208000035499 autosomal dominant nonsyndromic hearing loss 10 Diseases 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000002052 colonoscopy Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000000752 ionisation method Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000007855 methylation-specific PCR Methods 0.000 description 2
- 230000033607 mismatch repair Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 238000004153 renaturation Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000002579 sigmoidoscopy Methods 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006277 sulfonation reaction Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 108091006106 transcriptional activators Proteins 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000012808 vapor phase Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Chemical group OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 1
- 108700001666 APC Genes Proteins 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 102100036441 Amyloid-beta A4 precursor protein-binding family A member 2 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 239000004380 Cholic acid Chemical group 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 230000007118 DNA alkylation Effects 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000006429 DNA hypomethylation Effects 0.000 description 1
- 102100028735 Dachshund homolog 1 Human genes 0.000 description 1
- 108700001857 Drosophila eya Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 206010051635 Gastrointestinal tract adenoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000928677 Homo sapiens Amyloid-beta A4 precursor protein-binding family A member 2 Proteins 0.000 description 1
- 101000915055 Homo sapiens Dachshund homolog 1 Proteins 0.000 description 1
- 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 description 1
- 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000102542 Kara Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 102100036034 Thrombospondin-1 Human genes 0.000 description 1
- 108010079351 Tumor Suppressor Protein p14ARF Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical group C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 201000002758 colorectal adenoma Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000013578 denaturing buffer Substances 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Chemical group C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006326 desulfonation Effects 0.000 description 1
- 238000005869 desulfonation reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000011365 genetic imprinting Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-M hydrosulfide Chemical compound [SH-] RWSOTUBLDIXVET-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 238000001698 laser desorption ionisation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007758 mating behavior Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 102000015380 snRNP Core Proteins Human genes 0.000 description 1
- 108010039827 snRNP Core Proteins Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 150000003568 thioethers Chemical group 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02004551 | 2002-02-27 | ||
| EP02004551A EP1340818A1 (en) | 2002-02-27 | 2002-02-27 | Method and nucleic acids for the analysis of a colon cell proliferative disorder |
| PCT/EP2003/001457 WO2003072812A2 (en) | 2002-02-27 | 2003-02-13 | Method and nucleic acids for the analysis of colorectal cell proliferative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60317045D1 DE60317045D1 (de) | 2007-12-06 |
| DE60317045T2 true DE60317045T2 (de) | 2008-08-07 |
Family
ID=27675653
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60317045T Expired - Lifetime DE60317045T2 (de) | 2002-02-27 | 2003-02-13 | Verfahren und nukleinsäuren zur analyse von störungen der proliferation kolorektaler zellen |
| DE60327600T Expired - Lifetime DE60327600D1 (de) | 2002-02-27 | 2003-02-27 | Verfahren und nukleinsäuren zur analyse von kolonkrebszellen |
| DE60335245T Expired - Lifetime DE60335245D1 (de) | 2002-02-27 | 2003-02-27 | Verfahren und nukleinsäuren zur analyse von kolonkrebs |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60327600T Expired - Lifetime DE60327600D1 (de) | 2002-02-27 | 2003-02-27 | Verfahren und nukleinsäuren zur analyse von kolonkrebszellen |
| DE60335245T Expired - Lifetime DE60335245D1 (de) | 2002-02-27 | 2003-02-27 | Verfahren und nukleinsäuren zur analyse von kolonkrebs |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US8691503B2 (enExample) |
| EP (4) | EP1340818A1 (enExample) |
| JP (3) | JP2005518218A (enExample) |
| AT (3) | ATE376596T1 (enExample) |
| AU (3) | AU2003210265A1 (enExample) |
| CA (1) | CA2451982A1 (enExample) |
| DE (3) | DE60317045T2 (enExample) |
| ES (2) | ES2295607T3 (enExample) |
| WO (3) | WO2003072812A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9201067B2 (en) * | 2003-03-05 | 2015-12-01 | Posco | Size-controlled macromolecule |
| EP1340818A1 (en) | 2002-02-27 | 2003-09-03 | Epigenomics AG | Method and nucleic acids for the analysis of a colon cell proliferative disorder |
| US20040029128A1 (en) * | 2002-08-08 | 2004-02-12 | Epigenomics, Inc. | Methods and nucleic acids for the analysis of CpG dinucleotide methylation status associated with the calcitonin gene |
| EP1709204A1 (en) * | 2004-01-23 | 2006-10-11 | Lingvitae AS | Improving polynucleotide ligation reactions |
| WO2005089414A2 (en) * | 2004-03-17 | 2005-09-29 | The Johns Hopkins University | Neoplasia diagnostic compositions and methods of use |
| US7943308B2 (en) * | 2004-06-23 | 2011-05-17 | Epigenomics Ag | Methods and nucleic acids for the detection of metastasis of colon cell proliferative disorders |
| KR100617649B1 (ko) | 2004-09-24 | 2006-09-04 | (주)지노믹트리 | 대장암 특이적 발현감소 유전자의 메틸화된 프로모터를 함유하는 암 진단용 조성물 및 그 용도 |
| EP3342877B1 (en) * | 2004-09-30 | 2020-01-29 | Epigenomics AG | Method for providing dna fragments derived from an archived sample |
| US7932027B2 (en) | 2005-02-16 | 2011-04-26 | Epigenomics Ag | Method for determining the methylation pattern of a polynucleic acid |
| EP1693468A1 (en) | 2005-02-16 | 2006-08-23 | Epigenomics AG | Method for determining the methylation pattern of a polynucleic acid |
| PT1871912E (pt) | 2005-04-15 | 2012-05-25 | Epigenomics Ag | Método para determinar metilação de adn em amostras de sangue ou urina |
| US20100143899A1 (en) * | 2005-05-17 | 2010-06-10 | University Of Vermont And State Agricultural College | Methods and products for diagnosing cancer |
| DK2081950T3 (da) * | 2006-09-21 | 2013-06-03 | Nuclea Biomarkers Llc | Med irinotecanbehandling forbundne ekspressionsprofiler |
| US8445442B2 (en) * | 2007-04-26 | 2013-05-21 | University Of Vermont And State Agricultural College | CCL18 and CCL3 methods and compositions for detecting and treating cancer |
| WO2009045370A2 (en) * | 2007-09-28 | 2009-04-09 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
| MY188455A (en) * | 2007-10-19 | 2021-12-09 | Genentech Inc | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
| CN102099485A (zh) * | 2007-10-23 | 2011-06-15 | 临床基因组学有限公司 | 诊断新生物的方法-ⅱ |
| KR100969692B1 (ko) * | 2008-01-18 | 2010-07-14 | 한국생명공학연구원 | 대장암 과발현 유전자를 이용한 대장암 진단 마커 |
| US20100112713A1 (en) * | 2008-11-05 | 2010-05-06 | The Texas A&M University System | Methods For Detecting Colorectal Diseases And Disorders |
| US20120053071A1 (en) * | 2008-12-18 | 2012-03-01 | Koninklijke Philips Electronics N.V. | Method for the detection of dna methylation patterns |
| WO2012106525A2 (en) | 2011-02-02 | 2012-08-09 | Exact Sciences Corporation | Digital sequence analysis of dna methylation |
| AU2012324545A1 (en) * | 2011-10-17 | 2014-06-05 | King Abdullah University Of Science And Technology | Composite biomarker for non-invasive screening, diagnosis and prognosis of colorectal cancer |
| US9598735B2 (en) * | 2012-11-14 | 2017-03-21 | JBS Science Inc. | Detection of a panel of urine DNA markers for HCC screening and disease management |
| EP2886659A1 (en) | 2013-12-20 | 2015-06-24 | AIT Austrian Institute of Technology GmbH | Gene methylation based colorectal cancer diagnosis |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) * | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5023090A (en) * | 1989-08-16 | 1991-06-11 | Levin Robert H | Topical compositions containing LYCD and other topically active medicinal ingredients for the treatment of ACNE |
| US5457183A (en) * | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
| US5744101A (en) * | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5580722A (en) * | 1989-07-18 | 1996-12-03 | Oncogene Science, Inc. | Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease |
| US5180808A (en) * | 1989-11-27 | 1993-01-19 | La Jolla Cancer Research Foundation | Versican core protein, nucleic acid sequences encoding the same, nucleic acid probes, anti-versican antibodies, and methods of detecting the same |
| US5245022A (en) * | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
| US5210015A (en) * | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| US5565552A (en) * | 1992-01-21 | 1996-10-15 | Pharmacyclics, Inc. | Method of expanded porphyrin-oligonucleotide conjugate synthesis |
| US5574142A (en) * | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| SE501439C2 (sv) | 1993-06-22 | 1995-02-13 | Pharmacia Lkb Biotech | Sätt och anordning för analys av polynukleotidsekvenser |
| US5837832A (en) * | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| DE69417918T2 (de) | 1993-11-30 | 2000-01-05 | Mcgill University, Montreal | Dna methyltransferase inhibierung |
| US5597696A (en) * | 1994-07-18 | 1997-01-28 | Becton Dickinson And Company | Covalent cyanine dye oligonucleotide conjugates |
| US6017704A (en) * | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US5786146A (en) * | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| WO1998032849A2 (en) | 1997-01-29 | 1998-07-30 | Institut Pasteur | Polynucleotide associated with the bo or bor syndrome, its corresponding polypeptide and diagnostic and therapeutic applications |
| DE19754482A1 (de) | 1997-11-27 | 1999-07-01 | Epigenomics Gmbh | Verfahren zur Herstellung komplexer DNA-Methylierungs-Fingerabdrücke |
| CA2330929A1 (en) * | 1998-06-06 | 1999-12-16 | Genostic Pharma Limited | Probes used for genetic profiling |
| US7700324B1 (en) * | 1998-11-03 | 2010-04-20 | The Johns Hopkins University School Of Medicine | Methylated CpG island amplification (MCA) |
| US5958773A (en) * | 1998-12-17 | 1999-09-28 | Isis Pharmaceuticals Inc. | Antisense modulation of AKT-1 expression |
| US6335170B1 (en) | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
| US6331393B1 (en) * | 1999-05-14 | 2001-12-18 | University Of Southern California | Process for high-throughput DNA methylation analysis |
| DE19935772C2 (de) * | 1999-07-26 | 2002-11-07 | Epigenomics Ag | Verfahren zur relativen Quantifizierung der Methylierung von Cytosin Basen in DNA-Proben |
| ATE373710T1 (de) * | 1999-07-30 | 2007-10-15 | Epidauros Ag Biotechnologie Ag | Polymorphismus im humanen mdr-1 gen und dessen verwendung |
| US20040029123A1 (en) * | 2000-03-15 | 2004-02-12 | Alexander Olek | Diagnosis of diseases associated with the cell cycle |
| DE10019058A1 (de) | 2000-04-06 | 2001-12-20 | Epigenomics Ag | Detektion von Variationen des DNA-Methylierungsprofils |
| AU2001287269A1 (en) | 2000-03-28 | 2001-10-08 | Chiron Corporation | Human genes and expression products |
| DE10029915B4 (de) * | 2000-06-19 | 2005-06-16 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierungen |
| AU2001277521A1 (en) * | 2000-06-30 | 2002-01-14 | Epigenomics Ag | Diagnosis of diseases associated with cell signalling |
| MXPA03001834A (es) * | 2000-09-01 | 2003-08-01 | Epigenomics Ag | Metodo para determinar el grado de metilacion de determinadas citocinas en adn genomico en el contexto de secuencia 5'-cpg-3'. |
| AU2002305051A1 (en) * | 2001-03-15 | 2002-10-03 | Clemson University | Polynucleotide encoding a gene conferring resistance to bacillus thuringiensis toxins |
| DE10120798B4 (de) * | 2001-04-27 | 2005-12-29 | Genovoxx Gmbh | Verfahren zur Bestimmung der Genexpression |
| US20030138793A1 (en) | 2001-06-10 | 2003-07-24 | Irm Llc, A Delaware Limited Liability Company | Molecular signatures of commonly fatal carcinomas |
| US20030215842A1 (en) * | 2002-01-30 | 2003-11-20 | Epigenomics Ag | Method for the analysis of cytosine methylation patterns |
| EP1340818A1 (en) | 2002-02-27 | 2003-09-03 | Epigenomics AG | Method and nucleic acids for the analysis of a colon cell proliferative disorder |
| WO2007123892A2 (en) * | 2006-04-17 | 2007-11-01 | Arqule Inc. | Raf inhibitors and their uses |
-
2002
- 2002-02-27 EP EP02004551A patent/EP1340818A1/en not_active Withdrawn
-
2003
- 2003-02-13 EP EP03742934A patent/EP1478784B1/en not_active Expired - Lifetime
- 2003-02-13 ES ES03742934T patent/ES2295607T3/es not_active Expired - Lifetime
- 2003-02-13 JP JP2003571492A patent/JP2005518218A/ja active Pending
- 2003-02-13 AT AT03742934T patent/ATE376596T1/de not_active IP Right Cessation
- 2003-02-13 DE DE60317045T patent/DE60317045T2/de not_active Expired - Lifetime
- 2003-02-13 WO PCT/EP2003/001457 patent/WO2003072812A2/en not_active Ceased
- 2003-02-13 US US10/482,823 patent/US8691503B2/en not_active Expired - Fee Related
- 2003-02-13 CA CA002451982A patent/CA2451982A1/en not_active Abandoned
- 2003-02-13 AU AU2003210265A patent/AU2003210265A1/en not_active Abandoned
- 2003-02-27 DE DE60327600T patent/DE60327600D1/de not_active Expired - Lifetime
- 2003-02-27 AU AU2003219002A patent/AU2003219002B2/en not_active Ceased
- 2003-02-27 AT AT03742964T patent/ATE491038T1/de not_active IP Right Cessation
- 2003-02-27 WO PCT/EP2003/002035 patent/WO2003072821A2/en not_active Ceased
- 2003-02-27 EP EP03714760A patent/EP1478778B1/en not_active Expired - Lifetime
- 2003-02-27 EP EP03742964A patent/EP1481095B1/en not_active Expired - Lifetime
- 2003-02-27 DE DE60335245T patent/DE60335245D1/de not_active Expired - Lifetime
- 2003-02-27 AU AU2003248349A patent/AU2003248349B2/en not_active Ceased
- 2003-02-27 US US10/506,111 patent/US20060246433A1/en not_active Abandoned
- 2003-02-27 JP JP2003571501A patent/JP2005518220A/ja active Pending
- 2003-02-27 JP JP2003571500A patent/JP2005518219A/ja active Pending
- 2003-02-27 AT AT03714760T patent/ATE431429T1/de not_active IP Right Cessation
- 2003-02-27 WO PCT/EP2003/002034 patent/WO2003072820A2/en not_active Ceased
- 2003-02-27 US US10/506,089 patent/US20060234224A1/en not_active Abandoned
- 2003-02-27 ES ES03714760T patent/ES2325363T3/es not_active Expired - Lifetime
-
2010
- 2010-06-04 US US12/794,449 patent/US9988683B2/en not_active Expired - Lifetime
-
2014
- 2014-02-21 US US14/186,984 patent/US20140179563A1/en not_active Abandoned
- 2014-11-25 US US14/553,566 patent/US20150275312A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60317045T2 (de) | Verfahren und nukleinsäuren zur analyse von störungen der proliferation kolorektaler zellen | |
| EP2045335B1 (en) | Methods for the analysis of cellular proliferative disorders | |
| AU2008207110B2 (en) | Methods and nucleic acids for analyses of cell proliferative disorders | |
| US20040115630A1 (en) | Method and nucleic acids for the analysis of astrocytomas | |
| US20050282157A1 (en) | Diagnosis of diseases associated with dna replication | |
| WO2005007830A2 (en) | Methods and compositions for diagnosis, staging and prognosis of prostate cancer | |
| JP2005518218A5 (enExample) | ||
| DE10348407A1 (de) | Prognostische und diagnostische Marker für Zell-proliferative Erkrankungen von Brustgeweben | |
| DE10132212B4 (de) | Verfahren zum Nachweis von Cytosin-Methylierung durch vergleichende Analyse der Einzelstränge von Amplifikaten | |
| DE20121960U1 (de) | Nukleinsäuren für die Diagnose von mit Metastase assoziierten Krankheiten | |
| EP1945806A1 (en) | Markers for the prediction of outcome of anthracycline treatment | |
| EP1778865A1 (en) | Methods and nucleic acids for the detection of metastasis of colon cell proliferative disorders | |
| DE10230692A1 (de) | Verfahren und Nukleinsäuren für die Analyse von Methylierungsmustern innerhalb des DD3-Gens | |
| DE10245779A1 (de) | Verfahren und Nukleinsäuren für die verbesserte Behandlung von proliferativen Erkrankungen von Brustzellen | |
| DE10317955A1 (de) | Verfahren und Nukleinsäuren für die verbesserte Behandlung von proliferativen Erkrankungen von Brustzellen | |
| DE20121975U1 (de) | Nukleinsäuren für die Differenzierung von Astrocytomen, Oligoastrocytomen und Oligodendrogliom-Tumorzellen | |
| DE20121978U1 (de) | Nukleinsäuren für die Analyse von Astrocytomen | |
| DE10255104A1 (de) | Verfahren und Nukleinsäuren für die Analyse von proliferativen Erkrankungen von Brustzellen | |
| DE20121973U1 (de) | Nukleinsäuren für die Diagnose von mit dem Zellzyklus assoziierten Krankheiten | |
| DE20121977U1 (de) | Nukleinsäuren für die Diagnose von mit Tumor-Suppressorgenen und Onkogenen assoziierten Krankheiten | |
| HK1202137B (en) | Methods and nucleic acids for analyses of cellular proliferative disorders | |
| HK1118868A (en) | Methods and nucleic acids for analyses of cellular proliferative disorders | |
| HK1118868B (en) | Methods and nucleic acids for analyses of cellular proliferative disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |